In this review:
STAMPEDE survival data
Docetaxel or bisphosphonates for M0/M1 disease?
Orteronel as switch therapy in mCRPC
Enzalutamide as neoadjuvant therapy
TAK-383: An oral GnRH antagonist
A novel risk-stratification biomarker
cfDNA as a prognostic biomarker in mCRPC
TMPRSS2-ERG predicts response in mCRPC
Please login below to download this issue (PDF)